Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENRICH
2024-514275-18-00Phase 3Authorised
- Sponsor
- Region Skåne
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of ibrutinib, rituximab, doxorubicin, vincristine, cyclophosphamide and 2 more in mantle cell lymphoma (MCL) (2 arms), sponsored by Region Skåne. Primary endpoint: Progression-free survival. Planned start Sep 2024; status: authorised.
02
Drugs
ibrutinibrituximabdoxorubicinvincristinecyclophosphamide
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2024-514275-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514275-18-00.